New hope for Crohn's scarring: drug trial targets gut fibrosis
NCT ID NCT07177118
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 25 times
Summary
This study tests a drug called risankizumab for people with a severe form of Crohn's disease that causes scarring and narrowing of the intestines. About 260 adults who have not improved with standard treatments will receive either the drug or a placebo. The goal is to see if the drug can stop the scarring from getting worse and improve symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.